Listeria monocytogenes-LLO-PSA vaccine ADXS31-142

{
  "id": "MLC-T-ONC-014848",
  "term": "Listeria monocytogenes-LLO-PSA vaccine ADXS31-142",
  "field": "Oncology and biomedicine",
  "definition": "A cancer vaccine containing a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a fusion protein composed of the tumor-associated antigen (TAA) human prostate-specific antigen (PSA) fused to a fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-LLO-PSA vaccine ADXS31-142, the expressed LLO-PSA is processed by antigen presenting cells (APCs), presented to the immune system by both major histocompatibility complex (MHC) I and II molecules, and activates the immune system to exert both an innate and adaptive immune response involving the recruitment and activation of T lymphocytes against PSA-expressing tumor cells as well as the inhibition of tumor-infiltrating T-regulatory cells (T regs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis.",
  "synonyms": [
    "Lm-LLO-PSA"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/listeria-monocytogenes-llo-psa-vaccine-adxs31-142/"
}